Amidst Ongoing Manufacturer Restrictions, 340B Covered Entities and Contract Pharmacies Get Creative

Start
Although 340B-participating covered entities likely don’t need the reminder, numerous manufacturers continue to significantly restrict 340B pricing available via traditional “bill to/ship to” contract pharmacy models, with some restrictions being in place for nearly three years. Many of these manufacturer policies have become more restrictive over time, further reducing the availability of a once-potentially significant 340B benefit for covered entities. Although these policies (and HRSA’s…
By: Quarles & Brady LLP
Previous Story

ALCOA Denied Summary Judgment Where Question of Fact Exists

Next Story

Zoom Reverses Course on Contemplated Use of Customer Content to Train Artificial Intelligence